CMPS
The Q2 headline: less science project, more launch prep
Compass Pathways says the COMP360 story is getting sturdier. In its second-quarter 2026 update, the company highlighted positive Phase 3 readouts for treatment-resistant depression, including durability out to six months. That matters because biotech dreams are fun until the data show up — and here, the data are doing some heavy lifting.
The FDA runway is getting paved
The company says it’s moving ahead with its rolling NDA submission for COMP360 and has already started getting some modules reviewed by the FDA. Management still expects to finish the filing in Q4 2026, with the possibility of accelerated approval hanging out in the background like a very tempting bonus level.
Cash, commercial prep, and the not-so-glamorous stuff
Compass also said it had $433 million in cash as of June 30, which should carry it through launch and into 2028. That’s the kind of sentence investors love in biotech: fewer “going concern” nightmares, more actual launch planning.
On the operating side, the company is building out a commercial team, preparing interventional psychiatry sites, and working with payers on reimbursement. In other words, the science may be the headline, but the real work now looks a lot like logistics, training, and persuasion.
Why investors should care
The bullish case here is simple: if COMP360 keeps clearing regulatory and commercial hurdles, Compass could go from “promising pipeline” to “actual product company.” The catch, as always, is that psychedelic medicine still has to make the jump from fascinating to reimbursable. Big picture: the road to launch is looking clearer, but it’s still a road, not a teleportation device.